RMS Regrow attains milestone in
regenerative medicine with FDA India approval for CHONDRON
Is knee replacement now history for young
arthritis?
·
First company in India to receive a market authorization and sale license
for cell therapy product in Indiafor Chondron® ACI
·
Chondron®
ACIis India’s first ‘Make in India’ Stem cell success
story
·
RMS Regrow
is the 1st company in India to offer cell therapy in orthopedic products.
·
Chondron®
ACI (Autologous Chondrocyte
Implantation) is indicated for
the use of articular cartilage defects of the knee, ankle and shoulder joints
The Ministry
of Health, India and DCGI have granted Market Authorization for India’s First
Cell Therapy Product of India that is Chondron® ACI by Regenerative Medical Services Regrow. Chondron® ACI is indicated for treatment of cartilage defects of
the joints. It uses the body's own autologous cartilage cells which are cultured and
multiplied for 3-4 weeks at Regrow’sCell Processing Centre. The cultured cells
are then implanted into the patient's damaged joint leading to new cartilage regeneration, avoiding the need of early joint replacement.
Speaking onthis, Chief Executive
Officer &Managing Director, RMS Regrow, Mr. YashSanghavi said, “We are immensely
happy with the FDA approval for Chondron®
ACI. We are the
first in the country and fourth in the world to achieve this FDA approval.We
are creating new age cartilage regeneration procedure which optimizes the
chances of healing due to the use of the body’s own cells. Patients can now
expect a care free future with this treatment and RMS Regrow offers a perfect
PEN solution (P -Permanent, E –Easy, N-Natural biological) to the
patients”.
Company Chief Scientific officer &Executive
Director, RMS Regrow, Mr.SatyenSanghavi said, “Today,knee pain is the
most common ailment in every household. Osteoarthritis is the most prevalent form of
arthritis, affecting over 15 million adults every year, with the number likely
to escalate to over 60 million by 2025. Knee implants are expensive and the
recovery of the cartilage is not fast. Chondron®
ACIhas 97%
success rate with fast recovery, as observed in over 4-5 lakh cases performed
worldwide. RMS Regrow is proud to announce the FDA approval for Chondron® ACI and it is proprietary and
patented by RMS Regrow.”
Advantages of Chondron® ACI
·
Regeneration of
cartilage instead of replacing your entire knee
·
Minimally invasive personalized treatment
·
Increased quality of life
·
Resume complete physical activity , including of
professional sports
·
Cost Effective
·
Joint preservation providing Long term relief
Chondron® ACI is recommended for patients of 15-65 years age
group. It is imperative for a patient to
go through rehabilitation process for a minimum of six weeks. The
rehabilitation process is performed in the guidance of the doctor and the
physiotherapist. There is also medical insurance reimbursement available with Chondron® ACI.
In India, Osteoarthritis is the
most prevalent form of arthritis, affecting over 15 million adults every year.
There is no specific treatment proven as yet that can reverse the joint damage
caused by osteoarthritis. Hence the objectives of Osteoarthritis management are
to reduce the level of pain, reduce inflammation, slow cartilage degradation,
improve function and reduce disability.
There are about 4-5 lakhs of
knee, ankle, shoulder and hip replacement revision surgeries being performed in
India annually and the number is only going up every year. An artificial knee
will only last about a decade before wearing out. So if you are under 60, you
will have to undergo several more ‘revisions’ in your lifetime. Chondron® ACI helps for better solution
with effective and fast term results. Similar nature products for Chondron® ACI have been available in use
since 2001 in countries such as USA, Europe including UK & South Korea and
being reimbursed by their respective Health agencies.
About RMS Regrow:
Regenerative Medical Services
Pvt. Ltd. is the first Indian Biotechnology Company established in the year
2009 to introduce cutting edge technology platform for regenerative medicine in
India. Vision of Regenerative Medical Services Pvt. Ltd. is to contribute in
improving human healthcare by delivering safe and effective patient specific
regenerative medical treatment.
The aim of regenerative medicine
is to replace, repair or enhance the function of damaged tissue or organs by
accelerating and securing natural process with autologous stem cell therapy via
minimally invasive techniques without side effects.
The company is headquartered in
Mumbai, India and has a best in class Cell Processing Centre (CPCTMatLonavala.
Our lab has been awarded & certified as India’s only Center with Good
Manufacturing Practices (GMP), Good Laboratory Practices (GLP).). The Quality
Management System is also certified by ISO 13485:2003 by the British Standards
Institute.
RMS has two dimensions Regrow
therapy &Babycell stem cell banking.
Awards and Recognition:
o 39th
Skoch Award for India’s Best SME’s in the year 2015
o Product
Innovation Award by Asian Confederation of Businesses & Starts of the
Industry
o Worldwide
Achievers Healthcare Excellence Award by Govt of India in the year 2013
o ET
Now Leaders of Tomorrow in the year 2011 and 2012
o Featured
on CNBC show, Young Turks in the year 2012
o 2015
Leaders Awards - Healthcare Innovator Enterprise of the Year (Biotechnology)
o GMP,
ISO 13485:2013, GLP & accredited by BSI for Laboratory since 2010
o In
house R&D Unit is certified by Department of Scientific & Industrial
Research (DSIR), Ministry of Science & Technology
No comments:
Post a Comment